It is currently trading at $2.25 which is marginally over $2.14, the stock’s 50 day moving average and which is marginally higher than the 200 day moving average of $2.14. The 50 day moving average was up by +5.35% whereas the 200 day moving average was up $0.11 or +5.35%. Catabasis Pharmaceuticals, Inc. shares had a trading volume of 266K in the last trading session. Overall, volume was up 44.71% over the stocks normal daily volume.
Short traders are more bullish on the company recently if you pay attention to the fall in short interest. The firm recorded a fall in short interest from September 15, 2017 to September 29, 2017 of -63.96%. Short interest decreased 284,137 over that period. With short interest at 160,114 and short average daily volume at 1,325,115, days to cover is 0.0 and the percentage of shorted shares was 0.01% on September 29.
The following firms have recently changed their position in CATB. Blackrock Inc. cut its investment by selling 16,148 shares a decrease of 86.7% as of 06/30/2017. Blackrock Inc. now holds 2,484 shares valued at $4,000. The total value of its holdings decreased 86.7%. Tower Research Capital LLC (trc) grew its ownership by buying 126 shares an increase of 9.7%. Tower Research Capital LLC (trc) controls 1,426 shares worth $2,000. The value of the position overall is down by 0.0%.
As of the end of the quarter Alyeska Investment Group, L.p. had disposed of 6,508 shares trimming its position 2.9%. The value of the company’s investment in Catabasis Pharmaceuticals, Inc. went from $354,000 to $303,000 decreasing 14.4% for the reporting period. As of quarter end Sphera Funds Management Ltd. had sold a total of 100,000 shares trimming its holdings by 25.8%. The value of the investment in CATB decreased from $621,000 to $409,000 a change of $212,000 quarter over quarter.
October 5 investment analysts at Citigroup held the stock rating at “Neutral” and moved down the price target from $8.00 to $3.50.
In the last earnings report the EPS was $-1.71 and is expected to be $-1.39 for the current year with 22,481,000 shares outstanding. Analysts expect next quarter’s EPS will be $-0.33 and the next full year EPS is projected to be $-1.10.
Catabasis Pharmaceuticals, Inc., launched on June 26, 2008, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Business’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Business’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Business’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Business’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA..